Search Results - "FIORI, GINEVRA"
-
1
Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases
Published in Clinical rheumatology (2021)“…Objective SB5 showed comparable efficacy and safety profile in respect to adalimumab originator (ADA) in randomized clinical trials of rheumatoid arthritis…”
Get full text
Journal Article -
2
The positive side of the coin: Sars-Cov-2 pandemic has taught us how much Telemedicine is useful as standard of care procedure in real life
Published in Clinical rheumatology (01-02-2022)“…Patients and health workers were at high risk of infection during the Sars-Cov-2 pandemic lockdown. For this reason, other medical and clinical approaches such…”
Get full text
Journal Article -
3
The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases
Published in Therapeutic advances in musculoskeletal disease (2020)“…Aims: Switching from originator to biosimilar is part of current practice in inflammatory rheumatic musculoskeletal diseases (iRMDs) such as rheumatoid…”
Get full text
Journal Article -
4
Baricitinib in the treatment of rheumatoid arthritis: clinical and ultrasound evaluation of a real-life single-centre experience
Published in Therapeutic advances in musculoskeletal disease (2021)“…Background: Ultrasound (US) is useful in monitoring RA patients, with the US7 score allowing grey-scale and power-Doppler (PD) semi-quantitative evaluation of…”
Get full text
Journal Article -
5
Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis
Published in Therapeutic advances in musculoskeletal disease (2021)“…Aims: Medical and non-medical switching strategies have been adopted in Europe in the last few years. We aimed to investigate persistence on treatment with a…”
Get full text
Journal Article -
6
Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases
Published in European journal of rheumatology (01-10-2021)“…Osteoporosis (OP) can complicate the course of rheumatic musculoskeletal diseases (RMDs) and connective tissue diseases (CTDs). Denosumab, a monoclonal…”
Get full text
Journal Article -
7
Flow-Mediated Vasodilation and Carotid Intima-Media Thickness in Systemic Sclerosis
Published in Annals of the New York Academy of Sciences (01-06-2007)“…: Increased evidence suggests an accelerated macrovascular disease in systemic sclerosis (SSc). Brachial artery flow‐mediated vasodilation (FMD) and carotid…”
Get full text
Journal Article -
8
Exercise Doppler Echocardiography Identifies Preclinic Asymptomatic Pulmonary Hypertension in Systemic Sclerosis
Published in Annals of the New York Academy of Sciences (01-06-2007)“…: In systemic sclerosis (SSc), the involvement of the interstitium or vascular system of the lung may lead to pulmonary arterial hypertension (PAH). PAH is…”
Get full text
Journal Article -
9
-
10
Transitional connective tissue diseases: description of four cases
Published in Current rheumatology reviews (01-01-2014)“…The term overlap syndromes (OS) is used to define a group of disorders characterized by the presence, in the same patient, of clinical features typical for…”
Get more information
Journal Article -
11
Persistence of remission after lengthening of golimumab in inflammatory joint diseases
Published in Clinical and experimental rheumatology (01-05-2023)“…In refractory inflammatory joint diseases (IJDs) biological disease-modifying anti-rheumatic drugs (bDMARDs) may achieve remission. EULAR recommends bDMARD…”
Get more information
Journal Article -
12
Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study
Published in Annals of the rheumatic diseases (01-07-2013)“…To evaluate the safety and effectiveness of tocilizumab and abatacept in systemic sclerosis (SSc)-polyarthritis or SSc-myopathy. 20 patients with SSc with…”
Get more information
Journal Article -
13
Digital ulcers as a sentinel sign for early internal organ involvement in very early systemic sclerosis
Published in Rheumatology (Oxford, England) (01-01-2015)“…The aim of this study was to evaluate the presence of digital lesions in very early diagnosis of SSc (VEDOSS) patients and its possible association with…”
Get full text
Journal Article -
14
Calcinosis in systemic sclerosis: subsets, distribution and complications
Published in Rheumatology (Oxford, England) (01-09-2016)“…To retrospectively analyse the features of calcinosis in a cohort of SSc patients. Charts of SSc patients attending the Ulcer Unit of the Rheumatology…”
Get full text
Journal Article -
15
The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders
Published in The journal of allergy and clinical immunology in practice (Cambridge, MA) (01-11-2018)“…Hypersensitivity reactions (HRs) and loss of response (LOR) to infliximab (IFX) are related to drug immunogenicity characterized by antidrug antibodies (ADAs)…”
Get full text
Journal Article -
16
Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 digital lesions
Published in Rheumatology (Oxford, England) (01-07-2010)“…Objective. To evaluate in SSc, the frequency of digital lesions and the morphology, characteristics, natural course and time to healing of 1614 digital ulcers…”
Get full text
Journal Article -
17
Autologous Mesenchymal Stem Cells Foster Revascularization of Ischemic Limbs in Systemic Sclerosis A Case Report
Published in Annals of internal medicine (16-11-2010)“…Mesenchymal stem cells can differentiate into endothelial cells and participate in angiogenesis in adults. In experimental models of acute myocardial…”
Get full text
Journal Article -
18
Premedication prevents infusion reactions and improves retention rate during infliximab treatment
Published in Clinical rheumatology (01-11-2016)“…Infliximab (IFX) is an anti-tumor necrosis factor-alpha antibody used to treat inflammatory joint diseases. Infusion reactions (IR) can occur during and after…”
Get full text
Journal Article -
19
Assessment, Definition, and Classification of Lower Limb Ulcers in Systemic Sclerosis: A Challenge for the Rheumatologist
Published in Journal of rheumatology (01-03-2016)“…To evaluate pathogenesis and clinical features of lower limb ulcers in systemic sclerosis (SSc) and to propose a classification that could be used in clinical…”
Get full text
Journal Article -
20
Long-term treatment of scleroderma-related digital ulcers with iloprost: a cohort study
Published in Clinical and experimental rheumatology (01-09-2017)“…Raynaud's phenomenon and chronic/recurrent digital ulcers (DU) are main features of systemic sclerosis (SSc). Their treatment includes both systemic (i.e.,…”
Get full text
Journal Article